Midostaurin is an FMS-like tyrosine kinase 3 receptor (FLT3) inhibitor that provides renewed hope for treating acute myeloid leukaemia (AML). The limited efficacy of this compound as a monotherapy contrasts with that of its synergistic combination with standard cytarabine and daunorubicin (Dau), suggesting a therapeutic benefit that is not driven only by FLT3 inhibition. In an AML context, the activity of the enzyme aldo-keto reductase 1C3 (AKR1C3) is a crucial factor in chemotherapy resistance, as it mediates the intracellular transformation of anthracyclines to less active hydroxy metabolites. Here, we report that midostaurin is a potent inhibitor of Dau inactivation mediated by AKR1C3 in both its recombinant form as well as during its overexpression in a transfected cell model. Likewise, in the FLT3- AML cell line KG1a, midostaurin was able to increase the cellular accumulation of Dau and significantly decrease its metabolism by AKR1C3 simultaneously. The combination of those mechanisms increased the nuclear localization of Dau, thus synergizing its cytotoxic effects on KG1a cells. Our results provide new in vitro evidence of how the therapeutic activity of midostaurin could operate beyond targeting the FLT3 receptor.

Department of Biochemical Sciences Charles University Faculty of Pharmacy Akademika Heyrovského 1203 50005 Hradec Králové Czech Republic

Zobrazit více v PubMed

Bailly JD, Muller C, Jaffrézou JP, Demur C, Cassar G, Bordier C, Laurent G (1995) Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia 9:799–807 PubMed

Bains OS, Grigliatti TA, Reid RE, Riggs KW (2010) Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J Pharmacol Exp Ther 335(3):533–545. https://doi.org/10.1124/jpet.110.173179 PubMed DOI

Bains OS, Szeitz A, Lubieniecka JM, Cragg GE, Grigliatti TA, Riggs KW, Reid RE (2013) A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin. J Pharmacol Exp Ther 347(2):375–387. https://doi.org/10.1124/jpet.113.206805 PubMed DOI

Berger T, Rozovski U, Moshe Y, Yaari S, Hellmann I, Apel A, Wolach O (2019) Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission and higher transplant rates in remission: a multi-center historical control study. HemaSphere 3:95. https://doi.org/10.1097/01.hs9.0000559360.94558.03 DOI

Birtwistle J, Hayden RE, Khanim FL, Green RM, Pearce C, Davies NJ, Bunce CM (2009a) The aldo-keto reductase AKR1C3 contributes to DNA damage in myeloid cells: implications for leukemogenesis. Mut Res 662:67–74. https://doi.org/10.1016/j.mrfmmm.2008.12.010 DOI

Birtwistle J, Hayden RE, Khanim FL, Green RM, Pearce C, Davies NJ, Bunce CM (2009b) The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: Implications for leukemogenesis. Mut Res 662(1–2):67–74. https://doi.org/10.1016/j.mrfmmm.2008.12.010 DOI

Bogason A, Masquelier M, Lafolie P, Skogastierna C, Paul C, Gruber A, Vitols S (2010) Daunorubicin metabolism in leukemic cells isolated from patients with acute myeloid leukemia. Drug Metab Lett 4(4):228–232. https://doi.org/10.2174/187231210792928260 PubMed DOI

Byrns MC, Duan L, Lee SH, Blair IA, Penning TM (2010) Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer. J Steroid Biochem Mol Biol 118(3):177–187. https://doi.org/10.1016/j.jsbmb.2009.12.009 PubMed DOI

Cihalova D, Ceckova M, Kucera R, Klimes J, Staud F (2015) Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro. Biochem Pharmacol. https://doi.org/10.1016/j.bcp.2015.08.099 PubMed DOI

Copeland RA (2013) Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists. Wiley, New Jerssey. https://doi.org/10.1002/9781118540398 DOI

Desmond JC, Mountford JC, Drayson MT, Walker EA, Hewison M, Ride JP, Bunce CM (2003) The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Can Res 63(2):505–512

Dozmorov MG, Azzarello JT, Wren JD, Fung K-M, Yang Q, Davis JS, Lin H-K (2010) Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression. BMC Cancer 10(1):672. https://doi.org/10.1186/1471-2407-10-672 PubMed DOI PMC

Edwardson DW, Narendrula R, Chewchuk S, Mispel-beyer K, Jonathan PJ, Parissenti AM (2015) Role of drug metabolism in the cytotoxicity and clinical efficacy of anthracyclines. Curr Drug Metab 16:412–426 DOI

Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Meyer T (2000) PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anti-Cancer Drug Des 15:17–28

Fardel O, Yen LEAPA, Courtois A, Drenou B (1998) Differential expression and activity of P-glycoprotein and multidrug resistance-associated protein in CD34-positive KGla leukemic cells. Int J Oncol 12:315–319 PubMed

Gary Gilliland D, Griffin JD (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood. https://doi.org/10.1182/blood-2002-02-0492 PubMed DOI

Hayden RE, Pratt G, Davies NJ, Khanim FL, Birtwistle J, Delgado J, Bunce CM (2009) Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dΔ12,14, PGJ2. Leukemia. https://doi.org/10.1038/leu.2008.283 PubMed DOI

He M, Wei MJ (2012) Reversing multidrug resistance by tyrosine kinase inhibitors. Chin J Cancer 31(3):126–133. https://doi.org/10.5732/cjc.011.10315 PubMed DOI PMC

Heibein AD, Guo B, Sprowl JA, MacLean DA, Parissenti AM (2012) Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization. BMC Cancer 12(1):1. https://doi.org/10.1186/1471-2407-12-381 DOI

Ho MM, Hogge DE, Ling V (2008) MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Exp Hematol. https://doi.org/10.1016/j.exphem.2007.11.014 PubMed DOI

Hofman J, Malcekova B, Skarka A, Novotna E, Wsol V (2014) Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3. Toxicol Appl Pharmacol 278(3):238–248. https://doi.org/10.1016/j.taap.2014.04.027 PubMed DOI

Hsiao SH, Lusvarghi S, Huang YH, Ambudkar SV, Hsu SC, Wu CP (2019) The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. Cancer Lett. https://doi.org/10.1016/j.canlet.2019.01.001 PubMed DOI

Ji N, Yang Y, Cai CY, Wang JQ, Lei ZN, Wu ZX, Kong D (2019) Midostaurin reverses ABCB1-mediated multidrug resistance, an in vitro study. Front Oncol. https://doi.org/10.3389/fonc.2019.00514 PubMed DOI PMC

Kayser S, Levis MJ, Schlenk RF (2017) Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis. Expert Rev Clin Pharmacol 10(11):1177–1189. https://doi.org/10.1080/17512433.2017.1387051 PubMed DOI

Khanim F, Davies N, Veliça P, Hayden R, Ride J, Pararasa C, Bunce C (2014) Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate. Br J Cancer 110(6):1506–1516. https://doi.org/10.1038/bjc.2014.83 PubMed DOI PMC

Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R, Small D (2006) Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. https://doi.org/10.1182/blood-2006-04-015743 PubMed DOI PMC

Luskin MR, DeAngelo DJ (2017) Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. Expert Rev Hematol 10(12):1033–1045. https://doi.org/10.1080/17474086.2017.1397510 PubMed DOI

Malatkova P, Wsol V (2014) Carbonyl reduction pathways in drug metabolism. Drug Metab Rev. https://doi.org/10.3109/03602532.2013.853078 PubMed DOI

Marzac C, Garrido E, Tang R, Fava F, Hirsch P, de Benedictis C, Legrand O (2011) ATP Binding Cassette transporters associated with chemoresistance: Transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients. Haematologica. https://doi.org/10.3324/haematol.2010.031823 PubMed DOI PMC

Matsunaga T, Yamaguchi A, Morikawa Y, Kezuka C, Takazawa H, Endo S, Hara A (2014) Induction of aldo-keto reductases (AKR1C1 and AKR1C3) abolishes the efficacy of daunorubicin chemotherapy for leukemic U937 cells. Anticancer Drugs 25(8):868–877. https://doi.org/10.1097/CAD.0000000000000112 PubMed DOI

Novotná E, Büküm N, Hofman J, Flaxová M, Kouklíková E, Louvarová D, Wsól V (2018a) Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile. Arch Toxicol 92(9):2845–2857. https://doi.org/10.1007/s00204-018-2258-0 PubMed DOI

Novotná E, Büküm N, Hofman J, Flaxová M, Kouklíková E, Louvarová D, Wsól V (2018b) Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): a promising therapeutic target for cancer treatment. Biochem Pharmacol 156:22–31. https://doi.org/10.1016/j.bcp.2018.08.001 PubMed DOI

Patnaik MM (2017) Midostaurin for the treatment of acute myeloid leukemia. Future Oncol 13(21):1853–1871. https://doi.org/10.2217/fon-2017-0160 PubMed DOI

Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP, Twelves C (2001) Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol. https://doi.org/10.1200/JCO.2001.19.5.1485 PubMed DOI

QuilletMary A, Mansat V, Duchayne E, Come MG, Allouche M, Bailly JD, Laurent G (1996) Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines. Leukemia 10(3):417–425

Quillet-Mary A, Mansat V, Duchayne E, Come MG, Allouche M, Bailly JD, Laurent G (1996) Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines. Leukemia 10(January):417–425 PubMed

Reiter K, Polzer H, Krupka C, Maiser A, Vick B, Rothenberg-Thurley M, Greif PA (2018) Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia. Leukemia 32(2):313–322. https://doi.org/10.1038/leu.2017.257 PubMed DOI

Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM (2018) Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. https://doi.org/10.1038/s41568-018-0005-8 PubMed DOI PMC

Shiraki T, Kamiya N, Shiki S, Kodama TS, Kakizuka A, Jingami H (2005) α, β-Unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor γ. J Biol Chem. https://doi.org/10.1074/jbc.M500901200 PubMed DOI

Škarydová L, Wsól V (2012) Human microsomal carbonyl reducing enzymes in the metabolism of xenobiotics: well-known and promising members of the SDR superfamily. Drug Metab Rev. https://doi.org/10.3109/03602532.2011.638304 PubMed DOI

Škarydová L, Živná L, Xiong G, Maser E, Wsól V (2009) AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact. https://doi.org/10.1016/j.cbi.2008.10.015 PubMed DOI

Skarydova L, Nobilis M, Wsól V (2013) Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro. Xenobiotica. https://doi.org/10.3109/00498254.2012.720048 PubMed DOI

Stansfield LC, Pollyea DA (2017) Midostaurin: a new oral agent targeting FMS-Like tyrosine kinase 3-mutant acute myeloid leukemia. Pharmacotherapy 37(12):1586–1599. https://doi.org/10.1002/phar.2039 PubMed DOI

Stirewalt DL, Radich JP (2003) The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. https://doi.org/10.1038/nrc1169 PubMed DOI

Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Griffin JD (2005) Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. https://doi.org/10.1182/blood-2004-03-0891 PubMed DOI PMC

Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Döhner H (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377(5):454–464. https://doi.org/10.1056/NEJMoa1614359 PubMed DOI PMC

Stone RM, Manley PW, Larson RA, Capdeville R (2018) Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv 2(4):444–453. https://doi.org/10.1182/bloodadvances.2017011080 PubMed DOI PMC

Swinney DC (2004) Biochemical mechanisms of drug action: What does it take for success? Nat Rev Drug Discov 3(9):801–808. https://doi.org/10.1038/nrd1500 PubMed DOI

Varatharajan S, Abraham A, Zhang W, Shaji RV, Ahmed R, Abraham A, Balasubramanian P (2012) Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. Eur J Clin Pharmacol. https://doi.org/10.1007/s00228-012-1291-9 PubMed DOI

Verma K, Zang T, Gupta N, Penning TM, Trippier PC (2016) Selective AKR1C3 inhibitors potentiate chemotherapeutic activity in multiple acute myeloid leukemia (AML) cell lines. ACS Med Chem Lett 7(8):774–779. https://doi.org/10.1021/acsmedchemlett.6b00163 PubMed DOI PMC

Verma K, Zang T, Penning TM, Trippier PC (2019) Potent and highly selective aldo–keto reductase 1C3 (AKR1C3) inhibitors act as chemotherapeutic potentiators in acute myeloid leukemia and T-cell acute lymphoblastic leukemia department of pharmaceutical sciences. Texas Tech Univ Health Sci. https://doi.org/10.1021/acs.jmedchem.9b00090 DOI

Wu S, Fu L (2018) Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. Mol Cancer 17(1):1–13. https://doi.org/10.1186/s12943-018-0775-3 DOI

Zeng CM, Chang LL, Ying MD, Cao J, He QJ, Zhu H, Yang B (2017) Aldo-keto reductase AKR1C1-AKR1C4: Functions, regulation, and intervention for anti-cancer therapy. Front Pharmacol 8:1–9. https://doi.org/10.3389/fphar.2017.00119 DOI

Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters

Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3